Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Platelet Activity in Vascular Surgery and Cardiovascular Events (PACE)

4 de diciembre de 2018 actualizado por: NYU Langone Health

Pathological and clinical studies have consistently demonstrated that abnormalities in thrombosis and hemostasis play a major role in the pathogenesis of atherosclerosis and atherothrombosis. Screening for abnormalities in thrombosis and hemostasis by measuring platelet activity, thrombin generation, and markers of coagulation have been proposed to identify individuals at high-risk for cardiovascular events, however, it remains a research tool not ready for implementation in standard care.

The proposed study will add to the growing understanding of platelet activity and markers of coagulation in cardiovascular disease; examine a comprehensive battery of platelet activity markers, thrombin generation, markers of coagulation, and inflammatory biomarkers in subjects undergoing vascular surgery; and will provide important data on the mechanism of increased platelet activity using micro RNA, RNA and DNA expression profiling. The study design is prospective and the main outcome measures are platelet activity, coagulation markers and incident cardiovascular and bleeding events.

Descripción general del estudio

Descripción detallada

The main aim is to determine whether preoperative platelet activity measurements are independently associated with short-term cardiovascular events in PAD patients undergoing open non-emergent lower extremity vascular surgery. We will characterize the platelet phenotype in 350 PAD patients before vascular surgery and use Cox proportional hazard models to determine the independent association of the platelet phenotype with risk of cardiovascular events in the first 30 days after surgery. The next aim is to determine whether platelet activity measurements are independently associated with long-term cardiovascular events in patients with established PAD. We will characterize the platelet phenotype following surgery and use Cox proportional hazards models to determine the independent association of the platelet phenotype with risk of long-term composite of myocardial infarction, stroke, or all-cause mortality with a mean follow-up of 2-years following vascular surgery. The final goal is to investigate mRNA-microRNA co-expression profiles in patients with and without elevated platelet activity measurements. We will establish the relationship between differentially expressed microRNAs and their target mRNAs related to platelet activity and identify new diagnostic markers and potential therapeutic targets of increased platelet activity.

Blood collection at three different time points (before surgery, following surgery while still in the hospital, and at the subjects' first return visit to the vascular surgeon following surgery) will allow us to assess the dynamic change in platelet activity, coagulation and inflammation during the perioperative period. We believe that markers of clotting and bleeding will change during the course of surgery, and that some of these markers may be used to help predict the likelihood of developing a clotting or bleeding event following surgery. The long-term goal is to develop a clinically useful assessment of platelet activity, thrombin generation, coagulation and inflammation for risk stratification that may ultimately serve as a target for therapeutic intervention.

Tipo de estudio

De observación

Inscripción (Actual)

289

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • New York
      • New York, New York, Estados Unidos, 10016
        • NYU Langone Medical Center and School of Medicine

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

21 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

The study's population will be obtained form NYU Langone Medical Center, Bellevue Hospital and the VA Hospital.

Descripción

Inclusion Criteria:

  1. Subjects undergoing non emergent lower extremity revascularization
  2. Use of aspirin within 48 hours prior to surgery
  3. Age > 21 years of age
  4. Able and willing to provide written informed consent for the study

Exclusion Criteria:

  1. Use of any therapeutic anticoagulant
  2. Use of any nonsteroidal antiinflammatory drug (ibuprofen, naproxen, etc.) within 72 hours
  3. Thrombocytopenia (platelet count<100) or Thrombocytosis (platelet count>500)
  4. Anemia (hemoglobin<9)
  5. Any known hemorrhagic diathesis

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
PAD and CLI patients
Subjects undergoing non emergent lower extremity revascularization

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Platelet activity measurements associated with short-term cardiovascular events in PAD patients
Periodo de tiempo: 30-days
To determine whether preoperative platelet activity measurements are independently associated with short-term cardiovascular events in PAD patients undergoing open non-emergent lower extremity vascular intervention. We will characterize the platelet phenotype in 350 PAD patients before vascular surgery and use Cox proportional hazard models to determine the independent association of the platelet phenotype with risk of cardiovascular events in the first 30 days after surgery.
30-days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Association between platelet activity measurements and long-term cardiovascular events in patients with established PAD
Periodo de tiempo: Average follow-up of 5-years
To determine whether platelet activity measurements are independently associated with long-term cardiovascular events in patients with established PAD. We will characterize the postoperative platelet phenotype following surgery and use Cox proportional hazards models to determine the independent association of the platelet phenotype with risk of long-term composite of myocardial infarction, stroke, or all-cause mortality with a mean follow-up of 2-years following vascular surgery.
Average follow-up of 5-years

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
mRNA-microRNA co-expression profiles in patients with and without elevated platelet activity measurements
Periodo de tiempo: 30-days
To investigate mRNA-microRNA co-expression profiles in patients with and without elevated platelet activity measurements. We will establish the relationship between differentially expressed microRNAs and their target mRNAs related to platelet activity and thus identify new diagnostic markers and potential therapeutic targets of increased platelet activity.
30-days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Jeffrey Berger, MD, New York University Director of Cardiovascular Thrombosis

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de marzo de 2014

Finalización primaria (Actual)

14 de junio de 2018

Finalización del estudio (Actual)

14 de junio de 2018

Fechas de registro del estudio

Enviado por primera vez

22 de enero de 2014

Primero enviado que cumplió con los criterios de control de calidad

3 de abril de 2014

Publicado por primera vez (Estimar)

8 de abril de 2014

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de diciembre de 2018

Última actualización enviada que cumplió con los criterios de control de calidad

4 de diciembre de 2018

Última verificación

1 de diciembre de 2018

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • 14-00531
  • R01HL114978 (Subvención/contrato del NIH de EE. UU.)

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Enfermedad cardiovascular

3
Suscribir